# Performance Evaluation of LumiraDx COVID-19 (SARS-CoV-2) Ag ULTRA Test (ASPIRE-2)

> **NCT05506618** · NA · UNKNOWN · sponsor: **LumiraDx UK Limited** · enrollment: 400 (actual)

## Conditions studied

- COVID-19

## Interventions

- **DIAGNOSTIC_TEST:** Nasal Swab
- **DIAGNOSTIC_TEST:** Nasopharyngeal swab

## Key facts

- **NCT ID:** NCT05506618
- **Lead sponsor:** LumiraDx UK Limited
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-06-30
- **Primary completion:** 2022-10-04
- **Final completion:** 2023-04-30
- **Target enrollment:** 400 (ACTUAL)
- **Last updated:** 2023-03-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05506618

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05506618, "Performance Evaluation of LumiraDx COVID-19 (SARS-CoV-2) Ag ULTRA Test (ASPIRE-2)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05506618. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*